Opinion|Videos|July 17, 2024
Evaluating Amivantamab and Lazertinib: Key Findings from the CHRYSALIS-2 Study at ASCO 2024
Author(s)Jason Porter, MD
A key opinion leader examines the combination therapy of amivantamab and lazertinib in the CHRYSALIS-2 study for treatment-naïve patients or those with 2 or more prior lines of therapy, and its potential implications for non-small cell lung cancer treatment.
Advertisement
Video content above is prompted by the following questions:
- Discuss the data that was presented at the ASCO 2024 on combination use amivantamab and lazertinib in the CHRYSALIS-2 study for patients who were treatment-naïve or had ≤ 2 prior lines.
- Based on this study, how do you think amivantamab plus lazertinib compares with other current therapies used for EGFR mutations in NSCLC?
- How might the safety data from this study impact treatment decisions and management strategies in clinical practice?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Articles
- Survival Outcomes in Advanced NSCLC Improved With Use of Cemiplimab
September 10th 2025
- Cancer-Specific Outcomes Improved With Adherence to Quality Metrics
September 3rd 2025
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Cumulative Atropine Not Associated With Increased Risk of Ocular Events in Children With Myopia
2
West Coast Health Alliance Releases First Vaccine Guidelines, Aiming to Replace CDC Recommendations
3
Hospitals in Underserved Communities Less Likely to Adopt Health Information Technology
4
Sotatercept Shows Right Heart Gains in PAH: Anjali Vaidya, MD
5